ASCO 2026 | EV-202 cohort 9: enfortumab vedotin + pembrolizumab as first-line treatment in PDL-1+ R/M HNSCC
Ari Rosenberg, MD, University of Chicago, Chicago, IL, discusses the results of the Phase II EV-202 study (NCT04225117), which investigated the combination of enfortumab vedotin and pembrolizumab for frontline PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). He notes that the objective response rate (ORR) was 39%, with responses enriched for HPV-positive patients. Dr Rosenberg also highlights the potential of antibody drug conjugates (ADCs) targeting Nectin-4, particularly in patients with oropharynx primary or HPV-positive tumors. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
